Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Last Close
3.40
Nov 17 • 3:59 PM ET Dollar change-0.14 Percentage change(-3.95%)
Aftermarket Close
3.40
Aftermarket • 7:30 PM ET Dollar change0.00 Percentage change(0.00%)
Index
RUT
Market Cap
346.77M
Enterprise Value
412.60M
Income
-30.05M
Sales
620.45M
Book/sh
-0.37
Cash/sh
0.36
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
641
IPO
Jun 04, 2020
P/E
-
Forward P/E
-
PEG
-
P/S
0.56
P/B
-
P/C
9.40
P/FCF
18.42
EV/EBITDA
-
EV/Sales
0.67
Quick Ratio
0.82
Current Ratio
1.11
Debt/Eq
-
LT Debt/Eq
-
Option/Short
Yes / Yes
EPS (ttm)
-0.29
EPS next Y
-0.09
EPS next Q
-0.04
EPS this Y
50.93%
EPS next Y
67.92%
EPS next 5Y
-
EPS past 3/5Y
-37.23% -17.58%
Sales past 3/5Y
25.81% 21.80%
EPS Y/Y TTM
54.77%
Sales Y/Y TTM
34.58%
EPS Q/Q
10.19%
Sales Q/Q
24.31%
Insider Own
29.95%
Insider Trans
-8.96%
Inst Own
39.50%
Inst Trans
4.25%
ROA
-17.11%
ROE
-3407.86%
ROIC
-56.59%
Gross Margin
15.68%
Oper. Margin
-3.26%
Profit Margin
-4.84%
SMA20
-38.03%
SMA50
-44.44%
SMA200
-29.02%
Trades
Shs Outstand
101.99M
Shs Float
71.45M
52W High
7.13 -52.31%
52W Low
2.32 46.55%
Volatility
12.63% 12.92%
ATR (14)
0.56
RSI (14)
28.96
Beta
0.54
Rel Volume
1.71
Avg Volume
2.34M
Volume
4,010,855
Perf Week
-21.66%
Perf Month
-47.37%
Perf Quarter
-48.95%
Perf Half Y
-17.07%
Perf YTD
-4.49%
Perf Year
-9.81%
Perf 3Y
47.51%
Perf 5Y
-62.01%
Perf 10Y
-
Prev Close
3.54
Price
3.40
Change %
-3.95%
Consensus
Strong Buy
Avg. Price Target
$9.25
Implied Upside
+172.1%
Analysts7incl. previous ratings
Rating Distribution7 Buy · 0 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Jul 06, 2026Initiated
LLake Street
Buy$10+194.1%
Nov 25, 2025Initiated
NNeedham
Buy$5+47.1%
Jul 23, 2025Initiated
NNoble Capital Markets
Outperform$8+135.3%
Jul 16, 2025Initiated
RILY logoRB. Riley Securities
Buy$6+76.5%
May 15, 2025Initiated
BBTIG Research
Buy$7+105.9%
Feb 26, 2024Resumed
JEF logoJJefferies
Buy$2.50-26.5%
Sep 14, 2022Initiated
GGuggenheim
Buy$7+105.9%
Aug 15, 2022Initiated
JEF logoJJefferies
Buy$10+194.1%
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Chernett Jorey10% OwnerNov 09 '26Buy3.6548,294176,2737,858,091Nov 10 06:33 PM
Chernett Jorey10% OwnerNov 06 '26Sale3.992,851,06111,375,7337,809,797Nov 10 06:33 PM
Hively BradDirectorAug 21 '26Sale6.51298,8531,946,310411,976Aug 24 05:11 PM
BRADFORD HIVELYDirectorAug 21 '26Proposed Sale6.54298,8531,954,499Aug 21 04:35 PM
Chernett Jorey10% OwnerAug 14 '26Buy6.5412,00078,48010,660,858Aug 17 10:13 AM
Chernett Jorey10% OwnerJul 21 '26Buy5.2718,00094,86010,648,858Jul 22 09:55 AM
Podnos YaleChief Medical OfficerJul 14 '26Option Exercise1.9023,45244,567277,501Jul 16 08:05 PM
Podnos YaleChief Medical OfficerJul 14 '26Sale6.4123,452150,340259,527Jul 16 08:05 PM
YALE PODNOSOfficerJul 14 '26Proposed Sale6.2523,452146,575Jul 14 04:33 PM
Chernett Jorey10% OwnerJul 10 '26Buy5.8515,00087,75010,630,858Jul 13 11:34 AM
Chernett Jorey10% OwnerJun 23 '26Buy5.0218,00090,36010,615,858Jun 24 09:31 AM
Podnos YaleChief Medical OfficerJun 08 '26Sale5.3823,451126,094259,527Jun 09 07:06 PM
YALE PODNOSOfficerJun 08 '26Proposed Sale4.8723,451114,206Jun 08 04:37 PM
Chernett Jorey10% OwnerJun 04 '26Buy4.7512,00057,00010,579,858Jun 05 09:38 AM
Chernett Jorey10% OwnerMay 20 '26Buy4.0733,500136,34510,567,858May 21 09:35 AM
Chernett Jorey10% OwnerMay 19 '26Buy4.055,00020,25010,534,358May 21 09:35 AM
Chernett Jorey10% OwnerMay 19 '26Buy4.0930,000122,70010,529,358May 20 12:25 PM
Kaushal MohitDirectorApr 14 '26Sale3.5057,286200,598211,016Apr 16 07:27 PM
Kaushal MohitDirectorApr 16 '26Sale3.5038,433134,535172,583Apr 16 07:27 PM
MOHIT KAUSHALDirectorApr 14 '26Proposed Sale3.3095,719315,873Apr 14 04:35 PM
Chernett Jorey10% OwnerApr 09 '26Buy3.1020,00062,00010,499,358Apr 13 09:03 AM
Chernett Jorey10% OwnerMar 27 '26Buy2.9627,42981,19010,479,358Mar 30 09:38 AM
Chernett Jorey10% OwnerMar 26 '26Buy3.1550,000157,50010,451,929Mar 27 09:34 AM
Chernett Jorey10% OwnerMar 24 '26Buy3.11125,000388,75010,401,929Mar 25 09:33 AM
Chernett Jorey10% OwnerMar 20 '26Buy3.3525,00083,75010,276,929Mar 23 09:33 AM
Chernett Jorey10% OwnerMar 13 '26Buy2.92263,000767,96010,115,944Mar 17 07:40 PM
Chernett Jorey10% OwnerMar 17 '26Buy3.4275,000256,50010,251,929Mar 17 07:40 PM
Chernett Jorey10% OwnerMar 16 '26Buy3.2960,985200,64110,176,929Mar 17 07:40 PM
Carter Robert RossChief Financial OfficerJan 02 '26Sale3.56247879235,122Jan 05 05:04 PM
Hively BradDirectorDec 15 '25Sale3.7713,33350,291683,721Dec 16 04:30 PM
BRADFORD DANIEL HIVELYDirectorDec 15 '25Proposed Sale3.7713,33350,291Dec 15 04:07 PM
Starling Oncology, Inc. provides cancer care treatment services. It operates through the following business segments: Dispensary, Patient Care, and Clinical Trials and Other. The company was founded in 2007 and is headquartered in Cerritos, CA.
M.B.A.Dr. Daniel Virnich FACHE
Chief Financial OfficerMr. Robert Carter
M.D.Dr. Yale D. Podnos F.A.C.S.
VP of Accounting & ControllerMr. Austin Lee
Chief Information OfficerMr. Rakesh Panda